ABBVAbbVieSigning up patients
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma · PDAC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 900 (planned)
- Started
- Apr 30, 2026
- Main results expected
- Jun 2031
- Fully finished
- Jun 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured over: through study completion, approximately 6 years
Phase 3: Overall Survival (OS)
Measured over: through study completion, approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07490301 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC